title: Physiological significance of plasma sulfoconjugated dopamine in patients with hypertension--clinical and experimental studies.
abstract: Sulfoconjugated catecholamines, especially dopamine sulfate, have recently attracted much attention because of the possibility of their conversion to active free dopamine by tissue arylsulfatase. In the present study, we have measured the plasma levels of free and sulfoconjugated dopamine in patients with hypertension and have investigated the physiological significance of sulfoconjugation. Results showed that the plasma level of dopamine sulfate in patients with essential hypertension was higher than the level in control subjects, and was highest in patients with renal hypertension. However, the plasma level of free dopamine showed no significant difference between patients with hypertension and normal subjects. Moreover, after normalization of blood pressure in hypertensive patients with medication, the plasma levels of conjugated dopamine decreased to almost the control value. In the experimental study, dopamine sulfate inhibited angiotensin II-induced aldosterone release from bovine adrenal cortical cells to a similar extent as produced by free dopamine. From these results, we have concluded that plasma sulfoconjugated dopamine may regulate free dopamine in the plasma of patients with hypertension, and it may have some physiological effects on blood pressure regulation.
authors: Department of Cardiovascular Surgery and Pharmacology, School of Medicine, University of Tokushima, Japan.
authors: M
authors: M
authors: Yoshizumi
authors: T
authors: T
authors: Kitagawa
authors: T
authors: T
authors: Hori
authors: I
authors: I
authors: Katoh
authors: H
authors: H
authors: Houchi
authors: T
authors: T
authors: Ohuchi
authors: M
authors: M
authors: Oka
mesh_terms: D000302:Adrenal Cortex / Q000187:drug effects / Q000378:metabolism*; D000328:Adult; D000450:Aldosterone / Q000378:metabolism; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D002417:Cattle; D004298:Dopamine / Q000031:analogs & derivatives* / Q000097:blood* / Q000138:chemical synthesis / Q000494:pharmacology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006977:Hypertension, Renal / Q000097:blood* / Q000503:physiopathology; D066298:In Vitro Techniques; D008099:Liver / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D051381:Rats; D012016:Reference Values
chemical_list: D000959:Antihypertensive Agents; D000804:Angiotensin II; C022807:dopamine 4-O-sulfate; D000450:Aldosterone; C007558:dopamine 3-O-sulfate; D002394:Catechol O-Methyltransferase; D004298:Dopamine